Skip to main content
. Author manuscript; available in PMC: 2021 Sep 8.
Published in final edited form as: Mol Cancer Ther. 2019 Nov 29;19(2):637–649. doi: 10.1158/1535-7163.MCT-19-0330

Figure 4. Combined inhibition of HDAC and FAK abolishes FAK kinase activity and regulates YAP localization.

Figure 4

A, Lysates from A549 (left) and Flo1 (right) cells treated as indicated were immunoblotted for FAK, phosphorylated FAK (Y397), GAPDH, histone H3, and acetylated (K-Ac) histone H3. Quantification of phosphorylated FAK (Y397) immunoblotting (bottom) is displayed as means ± SEM (n = 3 independent experiments). *, P < 0.05; **, P < 0.01 (one-way ANOVA). B, Lysates from A549 (left) and Flo1 (right) cells were immunoblotted for YAP, phosphorylated YAP (S127), FAK, phosphorylated FAK (Y397), and GAPDH at 5 and 24 hours post drug treatment. C, A549 (left) and Flo1 (right) cells were fixed and labeled with anti-YAP antibody after 24 hours of drug treatment. Scale bar, 50 μm. D, Quantification of nuclear and cytoplasmic anti-YAP labeling. Relative fluorescence intensity values of anti-YAP labeling in the nuclear (left) and cytoplasmic (right) cellular compartments were normalized to DMSO values and displayed as means ± SEM (n = 3 independent experiments). E, Lysates from Flo1 (top) and A549 (bottom) cells treated as indicated were immunoblotted for Axl and GAPDH. Quantification of Axl expression is displayed as means ± SEM (n = 3 independent experiments). *, P < 0.05; **, P < 0.01 (one-way ANOVA).